China Registry for Genetic / Metabolic Liver Diseases
China Registry for Genetic / Metabolic Liver Diseases
CR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver
 diseases from tertiary or secondary hospitals in mainland China. Demographics, diagnosis,
 laboratory test results, family history and prescriptions were recorded. Patients' whole
 blood and serum were collected for genetic testing and future researches. These patients will
 be followed-up every six to twelve months.
This web-based database was launched on June 13, 2015 and consists of tertiary or secondary
 hospitals with special interest and expertise on managing genetic/metabolic liver diseases
 patients across mainland China. The main inclusion criteria for this registration are
 patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary
 hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other
 genetic/metabolic liver diseases. At the first time of data entry, demographics, medical
 history, biochemistry and hematology results, radiology reports, diagnosis and treatment
 information were recorded. Patients' whole blood and serum were collected for molecular
 genetic testing and future researches. Then the registered patients will receive standard of
 care and be followed-up every 6 to 12 months. On each visit, biochemical, radiological
 reports, as well as clinical progress were recorded.
Inclusion Criteria:

 Patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary
 hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or
 other genetic/metabolic liver diseases.

 Exclusion Criteria:

 Patients who are unable or unwilling to provide informed consent.